当前位置: X-MOL首页全球导师 国内导师 › 徐田锋

个人简介

教育经历 2009.08-2014.07,中国科学院广州生物医药与健康研究院,药物化学,博士 2005.09-2009.06,山东师范大学,应用化学,学士 工作经历 2019.03-至今,课题组长,研究员,中国科学院上海药物研究所 2014.11-2019.02,博士后,美国密歇根大学安娜堡校区癌症中心

研究领域

可诱导蛋白降解的小分子药物的设计与开发 与肿瘤免疫相关的小分子激酶抑制剂的设计与开发

近期论文

查看导师新发文章 (温馨提示:请注意重名现象,建议点开原文通过作者单位确认)

1.Xu, S.*; Aguilar, A.*; Xu, T.*; Zheng, K.*; Huang, L.*; Stuckey, J.; Chinnaswamy, K.; Bernard, D.; Fernández-Salas, E.; Liu, L., Wang, M.; McEachern, D.; Przybranowski, S.; Foster, C.; Wang, S., Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein–Protein Interaction, Angew Chem Int Edit. 2018, 57 (6), 1601-1605. (*共同第一作者) 2.Xu, T. *; Peng, T. *; Ren, X.*; Zhang, L.; Yu, L.; Luo, J.; Zhang, Z.; Tu, Z.; Tong, L.; Huang, Z.; Lu, X.; Geng, M.; Xie, H.; Ding, J.; Ding, K., C5-substituted pyrido [2, 3-d] pyrimidin-7-ones as highly specific kinase inhibitors targeting the clinical resistance-related EGFR T790M mutant, MedChemComm. 2015, 6(9), 1693-1697. 3.Xu, T. *; Zhang, L*.; Xu, S.; Yang, C.; Luo, J.; Ding, F.; Lu, X.; Liu, Y.; Tu, Z.; Li, L.; Pei, D.; Cai, Q.; Li, H.; Ren, X.; Wang, S.; Ding, K., Pyrimido[4,5-d]pyrimidin-4(1H)-one Derivatives as Selective Inhibitors of EGFR Threonine790 to Methionine790 (T790M) Mutants, Angew Chem Int Edit. 2013, 52(32),8387-8390. 4.Han, X.; Wang, C.; Qin, C.; Xiang, W.; Fernandez-Salas, E.; Yang, C.-Y.; Wang, M.; Zhao, L.; Xu, T.; Chinnaswamy, K.; Delproposto, J.; Stuckey, J.; Wang, S., Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019, 62 (2), 941-964 . 5.Yu, L.; Huang, M.; Xu, T.; Tong, L.; Yan, X.; Zhang, Z.; Xu, Y.; Yun, C.; Xie, H.; Ding, K.; Lu, X., A structure-guided optimization of pyrido [2, 3-d] pyrimidin-7-ones as selective inhibitors of EGFR L858R/T790M mutant with improved pharmacokinetic properties, Eur J Med Chem. 2017, 126, 1107-1117. 6.Xu, S.; Xu, T.; Zhang, L.; Zhang, Z.; Luo, J.; Liu, Y.; Lu, X.; Tu, Z.; Ren, X.; Ding, K., Design, Synthesis, and Biological Evaluation of 2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl Derivatives as New Irreversible Epidermal Growth Factor Receptor Inhibitors with Improved Pharmacokinetic Properties, J Med Chem. 2013, 56(21), 8803-8813.

推荐链接
down
wechat
bug